Toward personalized medicine in the pharmacotherapy of alcohol use disorder: Targeting patient genes and patient goals

American Journal of Psychiatry

Volumn 171, Issue 4, 2014, Pages 391-394

  Batki, Steven L ^a   Pennington, David L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; BACLOFEN; DISULFIRAM; GABAPENTIN; NALTREXONE; ONDANSETRON; SEROTONIN TRANSPORTER; SERTRALINE; TOPIRAMATE;

ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOL INTOXICATION; ALCOHOL USE DISORDER; ALCOHOLISM; DBH GENE; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; GATA4 GENE; GENE; GENE TARGETING; GRIK1 GENE; HUMAN; OPRM1 GENE; PERSONALIZED MEDICINE; PHARMACOGENETICS; PRIORITY JOURNAL; RELAPSE; REVIEW; SLC6A4 GENE; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME;

ALCOHOLISM; FEMALE; FRUCTOSE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, KAINIC ACID;

EID: 84898754320     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2014.14010061     Document Type: Review

References (15)

1. Harris AH, Oliva E, Bowe T, Humphreys KN, Kivlahan DR, Trafton JA: Pharmacotherapy of alcohol use disorders by the Veterans Health Administration: patterns of receipt and persistence. Psychiatr Serv 2012; 63: 679-685
2. Kranzler HR, Covault J, Feinn R, Armeli S, Tennen H, Arias AJ, Gelernter J, Pond T, Oncken C, Kampman KM: Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. Am J Psychiatry 2014; 171: 445-452
3. Johnson BA, Ait-Daoud N: Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients. Curr Pharm Des 2010; 16:2103-2112
4. Ray LA, Miranda R Jr, MacKillop J, McGeary J, Tidey JW, Rohsenow DJ, Gwaltney C, Swift RW, Monti PM: A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. Exp Clin Psychopharmacol 2009; 17:122-129
5. Arias AJ, Sewell RA: Pharmacogenetically driven treatments for alcoholism: Are we there yet? CNS Drugs 2012; 26:461-476
6. Ray LA, Barr CS, Blendy JA, Oslin D, Goldman D, Anton RF: The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: A critical review. Alcohol Clin Exp Res 2012; 36:385-394
7. Kranzler HR, McKay JR: Personalized treatment of alcohol dependence. Curr Psychiatry Rep 2012; 14: 486-493
8. Kranzler HR, Armeli S, Tennen H, Covault J, Feinn R, Arias AJ, Pettinati H, Oncken C: A double-blind, randomized trial of sertraline for alcohol dependence: moderation by age of onset [corrected] and 5-hydroxytryptamine transporter-linked promoter region genotype. J Clin Psychopharmacol 2011; 31:22-30
9. Johnson BA, Ait-Daoud N, Seneviratne C, Roache JD, Javors MA, Wang XQ, Liu L, Penberthy JK, DiClemente CC, Li MD: Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am J Psychiatry 2011; 168:265-275
10. Kiefer F, Witt SH, Frank J, Richter A, Treutlein J, Lemenager T, Nöthen MM, Cichon S, Batra A, Berner M, Wodarz N, Zimmermann US, Spanagel R, Wiedemann K, Smolka MN, Heinz A, Rietschel M, Mann K: Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate. Pharmacogenomics J 2011; 11:368-374
11. Mutschler J, Abbruzzese E, Witt SH, Dirican G, Nieratschker V, Frank J, Grosshans M, Rietschel M, Kiefer F: Functional polymorphism of the dopamine b-hydroxylase gene is associated with increased risk of disulfiram-induced adverse effects in alcohol-dependent patients. J Clin Psychopharmacol 2012; 32:578-580
12. Anton RF, Oroszi G, O'Malley S, Couper D, Swift R, Pettinati H, Goldman D: An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) Study. Arch Gen Psychiatry 2008; 65:135-144 (Pubitemid 351222547)
13. Kim SG, Kim CM, Choi SW, Jae YM, Lee HG, Son BK, Kim JG, Choi YS, Kim HO, Kim SY, Oslin DW: A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcoholdependent patients. Psychopharmacology (Berl) 2009; 201:611-618
14. Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, O'Brien CP: A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003; 28:1546-1552 (Pubitemid 41070891)
15. Tidey JW, Monti PM, Rohsenow DJ, Gwaltney CJ, Miranda R Jr, McGeary JE, MacKillop J, Swift RM, Abrams DB, Shiffman S, Paty JA: Moderators of naltrexone's effects on drinking, urge, and alcohol effects in nontreatment- seeking heavy drinkers in the natural environment. Alcohol Clin Exp Res 2008; 32:58-66 (Pubitemid 350293891)